Selected Protease Inhibitors/Lopinavir Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Lopinavir may slow down how quickly your liver processes indinavir, nelfinavir, and saquinavir. Lopinavir may speed up how quickly your liver processes amprenavir and fosamprenavir. Amprenavir, fosamprenavir may slow down how quickly your liver processes lopinavir. Nelfinavir may speed up how quickly your liver processes lopinavir.

What might happen:

The amount of amprenavir, fosamprenavir, indinavir, nelfinavir, and saquinavir in your blood may increase and cause more side effects than normal. The amount of lopinavir in your blood may decrease and it may not work as well.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may need to adjust the dose of your medicines. Let your doctor know if you experience an unusual increase in thirst or urination, skin rash, mood changes, weight gain, tingling or numbness, yellowing of the skin or eyes, or unusual bleeding or bruising.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories December, 2019.
  • 2.Kaletra (lopinavir/ritonavir capsules) US prescribing information. Abbott Laboratories September, 2016.
  • 3.Agenerase (amprenavir) Capsules US prescribing information. GlaxoSmithKline May, 2005.
  • 4.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline March, 2019.
  • 5.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. March, 2019.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.